31
Participants
Start Date
November 1, 2007
Primary Completion Date
November 17, 2020
Study Completion Date
November 17, 2020
Dasatinib
"Phase I: First Cohort = 100 mg PO Daily x 28 days; Next Cohort = Dose Expansion or Reduction Based on Dose Limiting Toxicity (DLT) in Initial Cohort.~Phase II: Recommended Phase II Dose (RP2D) as determined with Phase I."
Zoledronic Acid
"Phase I: First Cohort = 4 mg IV Over 15 min. every 4 Weeks; Next Cohort = Dose Expansion or Reduction Based on Dose Limiting Toxicity (DLT) in Initial Cohort.~Phase II: Recommended Phase II Dose (RP2D) as determined with Phase I."
Duke University, Durham
University of Chicago, Chicago
University of Texas MD Anderson Cancer Center, Houston
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
M.D. Anderson Cancer Center
OTHER